Advertisement
Agios Says CHMP Adopts Positive Opinion For PYRUKYND To Treat Pyruvate Kinase Deficiency In Adults
(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion on September 15, 2022, recommending the granting of a marketing authorization for PYRUKYND (mitapivat) for the treatment of pyruvate kinase (PK) deficiency in adult patients.
PK deficiency is a rare, debilitating, lifelong hemolytic anemia. PYRUKYND is a first-in-class, oral PK activator that was recently approved by the U.S. Food and Drug Administration (FDA).
If approved by the European Commission (EC), PYRUKYND will be the first approved disease-modifying therapy for European patients with PK deficiency.
PYRUKYND was previously granted orphan drug designation by the EMA.
The positive CHMP opinion was based on results from two pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively.
Strong Jobs Data Limits Dollar's Losses Amidst Fiscal And Tariff Concerns
U.S. Small Business Confidence Erodes Slightly In June, Taxes Main Concern - NFIB
Sensex, Nifty End Modestly Higher As Trump Extends Trade Deal Deadline
UK Stocks Turning In Mixed Performance In Cautious Trade
CAC 40 Slightly Lower In Lackluster Trade
Australia Central Bank Unexpectedly Maintains Status Quo
European Shares Little Changed As Investors Assess Trump's Tariff Plans
